热门资讯> 正文
FDA对Vanda tradipitant部分临床搁置延长的重新审查
2025-11-29 00:25
- The US FDA is extending by a matter of days a re-review of a partial clinical hold on long-term studies of Vanda Pharmaceuticals' (VNDA) tradipitant for motion sickness.
- The agency was supposed to complete its review by Nov. 26, but due to personnel changes in the Center for Drug Evaluation and Research, that date has been extended to Dec. 5.
- The hold was placed due to safety concerns and a lack of chronic toxicity data.
- Separately, Vanda said that the FDA action date for its tradipitant NDA for prevention of vomiting caused by nausea is still scheduled for Dec. 30, adding that the agency has recently provided comments on proposed labeling, and labeling discussions are underway.
More on Vanda Pharmaceuticals
- Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality
- Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript
- Vanda's tradipitant can significantly reduce nausea in those taking a GLP-1
- Vanda a new buy at B. Riley on 'historic discount'
- Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals
推荐文章
美股机会日报 | 新一轮牛市已在路上？华尔街集体唱多美股，三大股指期货盘前齐涨；美股今日提前3小时休市
概率超80%！美联储12月降息已箭在弦上，降息将带来哪些交易机会？附个股名单
新股申购 | 纳芯微、卓越睿新今起招股，入场费分别为11716.99港元、7686.75港元
华盛早报 | 回调即买入！摩根大通高呼“超配”中国；阿里进军AI硬件市场；美团今日放榜
特斯拉前高管透露曾拆解中国电动汽车：他们“超级聪明”
11月28日外盘头条：黄金从近两周高点下滑 乌美代表团本周将会面 OPEC+料在周日会议上维持产量不变
港股开盘：恒指高开0.07% 科指跌0.1% ，科网股走弱 ，黄金股普涨， 创新药概念活跃
美股机会日报 | 经济数据改善？美国22日当周初请失业金人数创逾半年新低；英伟达市场主导地位或受挑战
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
